Biomerieux (France) Top Management
BIM Stock | EUR 112.70 2.10 1.90% |
Biomerieux employs about 12.1 K people. The company is managed by 10 executives with a total tenure of roughly 28196 years, averaging almost 2819.0 years of service per executive, having 1208.4 employees per reported executive. Analysis of Biomerieux's management performance can provide insight into the company performance.
Frederic Beseme Insider Head CSR |
Guillaume Bouhours Insider Ex CFO |
Biomerieux |
Biomerieux Management Team Effectiveness
The company has return on total asset (ROA) of 0.1008 % which means that it generated a profit of $0.1008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1751 %, meaning that it generated $0.1751 on every $100 dollars invested by stockholders. Biomerieux's management efficiency ratios could be used to measure how well Biomerieux manages its routine affairs as well as how well it operates its assets and liabilities.Biomerieux Workforce Comparison
Biomerieux SA is number one stock in number of employees category among its peers. The total workforce of Diagnostics & Research industry is currently estimated at about 479,436. Biomerieux holds roughly 12,084 in number of employees claiming about 2.52% of equities under Diagnostics & Research industry.
The company has Profit Margin (PM) of 0.16 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.21 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.21. Biomerieux SA Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Biomerieux SA Price Series Summation is a cross summation of Biomerieux price series and its benchmark/peer.
Biomerieux Notable Stakeholders
A Biomerieux stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biomerieux often face trade-offs trying to please all of them. Biomerieux's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biomerieux's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Frederic Beseme | Head CSR | Profile | |
Guillaume Bouhours | Ex CFO | Profile | |
Pierre Boulud | Chief Operations | Profile | |
Franois Lacoste | Ex RD | Profile | |
Mark Miller | Ex Affairs | Profile | |
Alexandre Merieux | Chairman CEO | Profile | |
Valerie Leylde | Communications HR | Profile | |
Sylvain Morgeau | Investor Relations | Profile | |
Pierre Charbonnier | Manufacturing Quality | Profile | |
Yasha Mitrotti | Ex Microbiology | Profile |
About Biomerieux Management Performance
The success or failure of an entity such as Biomerieux SA often depends on how effective the management is. Biomerieux management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biomerieux management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biomerieux management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
bioMrieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company was formerly known as B-D Mrieux. bioMrieux S.A. was founded in 1963 and is based in Marcy lEtoile, France. bioMrieux S.A. is a subsidiary of Institut Mrieux SA. BIOMERIEUX operates under Diagnostics Research classification in France and is traded on Paris Stock Exchange. It employs 11200 people.
Please note, the presentation of Biomerieux's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biomerieux's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biomerieux's management manipulating its earnings.
Biomerieux Workforce Analysis
Traditionally, organizations such as Biomerieux use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biomerieux within its industry.Biomerieux Manpower Efficiency
Return on Biomerieux Manpower
Revenue Per Employee | 279.4K | |
Revenue Per Executive | 337.6M | |
Net Income Per Employee | 49.7K | |
Net Income Per Executive | 60.1M | |
Working Capital Per Employee | 33.7K | |
Working Capital Per Executive | 40.7M |
Complementary Tools for Biomerieux Stock analysis
When running Biomerieux's price analysis, check to measure Biomerieux's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomerieux is operating at the current time. Most of Biomerieux's value examination focuses on studying past and present price action to predict the probability of Biomerieux's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomerieux's price. Additionally, you may evaluate how the addition of Biomerieux to your portfolios can decrease your overall portfolio volatility.
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |